celltrion
Scope
Date
~
-
Bio & Pharma
Celltrion applies for approval of Xolair biosimilar in Canada
South Korean biopharmaceutical company Celltrion Inc. announced on Wednesday that it has applied for CT-P39, a biosimilar of the treatment of asth...
Dec 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on US PBM preferred drug list
South Korea's Celltrion Healthcare Co. announced on Tuesday that its anti-cancer biosimilar Vegzelma (active ingredient: bevacizumab) was listed as ...
Dec 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Herzuma selected as funded brand in NZ
Celltrion Healthcare Co. announced on Thursday that its biosimilar anticancer drug Herzuma (active ingredient trastuzumab) for breast and gastr...
Dec 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion, Cyron to develop multi-specific antibody new drug
South Korea’s biopharmaceutical company Celltrion Inc. announced on Wednesday that it signed a joint research agreement with domestic startup ...
Dec 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare's Remsima SC to be launched in US in 2024
Celltrion Healthcare Co. announced on Thursday that its autoimmune disease treatment Zymfentra (the US product name for Remsima SC) is set to be lau...
Nov 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in Europe for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it applied for approval from the European Medicines Agency (EMA) for ...
Nov 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to supply Remsima to Brazil gov’t in three-year row
South Korea's Celltrion Healthcare Co. announced on Friday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for the B...
Nov 10, 2023 (Gmt+09:00)
-
Earnings
Celltrion enjoys record earnings on healthy biosimilar biz
South Korean pharmaceutical giant Celltrion Inc. logged record quarterly earnings on the strong performance of its key biosimilar products while exp...
Nov 07, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s approved merger removes hurdle to three-way combination
South Korea’s biosimilar drugmaker Celltrion group on Monday moved one step closer to the planned combination of its three major affiliates wi...
Oct 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets FDA approval for Remsima SC
South Korea's Celltrion Inc. announced on Monday it received a new drug approval for an autoimmune disease treatment Remsima SC (active ingredient i...
Oct 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare wins Remsima order in France, Italy
South Korea's Celltrion Healthcare Co. announced on Wednesday its autoimmune disease treatment Remsima (ingredient: infliximab) has won a bid for ho...
Oct 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare to supply Yuflyma to US pharmacy chain
South Korea's Celltrion Healthcare Co. has inked a deal with the US specialty pharmacy chain CarePartners Pharmacy to supply its autoimmune disease ...
Oct 16, 2023 (Gmt+09:00)
-
Bio & Pharma
Proxy adviser ISS backs drug giant Celltrion's merger plan
South Korean drug giant Celltrion Group has received a positive recommendation from Institutional Shareholder Services (ISS), a global leading proxy...
Oct 06, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Pharm gets GMP certification from Japan
Celltrion Pharm Inc. announced on Wednesday that its pre-filled syringe (PFS) production facility in Cheongju, North Chungcheong Province has obtain...
Sep 27, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets sales approval for Yuflyma in Japan
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it has secured approval from the Japanese Ministry of Health, Labou...
Sep 26, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion signs largest-ever quarterly deal with global sales affiliate
Celltrion Inc., a South Korean biopharmaceutical giant, said Monday it will provide biosimilars worth 423.6 billion won ($323.6 million), its larges...
Sep 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare to supply Yuflyma to five regional gov’ts in Italy
South Korea's Celltrion Healthcare Co. announced on Monday that it will supply its biosimilar Yuflyma (active ingredient: adalimumab) for the treatm...
Sep 18, 2023 (Gmt+09:00)
-
KOREA Investment Week
Celltrion builds clinical data bank for new biosimilars
The use of data and computing is a new paradigm in the biopharmaceutical industry, reducing the new drug development time and cost, Celltrion Inc. C...
Sep 12, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand new plant for drug products
South Korean biopharmaceutical firm Celltrion Inc. announced on Tuesday that it plans to enlarge its finished pharmaceuticals manufacturing facility...
Sep 05, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to release Stelara biosimilar in US from March 2025
South Korean biopharmaceutical company Celltrion Inc. announced on Friday that it has completed a patent agreement with Johnson & Johnson, the m...
Aug 25, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion considers listing holding firm after merger of 3 units
South Korean drug giant Celltrion Group will consider listing its holding company if necessary, after it completes the merger of three affiliates &n...
Aug 24, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion’s Vegzelma listed on prescription of 10 private US insurers
South Korea’s Celltrion Healthcare Co. announced on Wednesday that it has signed contracts with 10 insurance providers in the US to boost the ...
Aug 23, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion gets OK partial approval for phase 3 of biosimilar in Europe
South Korean biopharmaceutical company Celltrion Inc. announced on Tuesday that it has received approval from the European Medicines Agency (EMA) fo...
Aug 22, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to merge with global sales affiliate by end-2023
South Korean pharmaceutical giant Celltrion Group has begun procedures to merge biopharmaceuticals developer and producer Celltrion Inc. with global...
Aug 17, 2023 (Gmt+09:00)
-
Carbon neutrality
Samsung Biologics, Celltrion pledge major CO2 cuts
South Korea’s No. 1 biopharmaceutical company Samsung BioLogics Co. and No. 2 Celltrion Inc. produced higher CO2 emissions last year than in 2...
Jul 10, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion Healthcare launches Humira biosimilar Yuflyma in US
South Korean biopharmaceutical company Celltrion Healthcare on Monday said it launched the day before on the US market Yuflyma, a biosimilar of the ...
Jul 04, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion applies for approval in US for eye treatment biosimilar
South Korean biopharmaceutical company Celltrion Inc. on Friday said it applied for approval from the US Food and Drug Administration (FDA) for CT-P...
Jun 30, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion puts Takeda’s assets up for sale after 3 years
South Korea’s Celltrion Inc. has put its Japanese Takeda Pharmaceutical Co.'s primary care assets acquired in 2020 on sale as the biosimilar g...
Jun 18, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion wins phase 3 IND approval for Ocrevus biosimilar in US
South Korea's biopharmaceutical company Celltrion Inc. announced that it received on Thursday approval from the US Food and Drug Administration (FDA...
Jun 15, 2023 (Gmt+09:00)
-
Bio & Pharma
Celltrion to expand biosimilar portfolio to 11 by 2025
South Korea's biopharmaceutical company Celltrion Inc. announced on Tuesday that it plans to beef up its portfolio by applying for regulatory approv...
Jun 13, 2023 (Gmt+09:00)